Eden C, Syrnioti G, Johnson J, Moore A, Liu A, Zhou X
JAMA Surg. 2025; .
PMID: 40072414
PMC: 11904798.
DOI: 10.1001/jamasurg.2025.0100.
Porter I, Berko H, Mafuvadze B
Cureus. 2025; 17(1):e78293.
PMID: 40026926
PMC: 11872145.
DOI: 10.7759/cureus.78293.
Guliyev M, Guren A, Ozge E, Colak R, Majidova N, Alkan Sen G
Cancers (Basel). 2025; 17(4).
PMID: 40002286
PMC: 11853050.
DOI: 10.3390/cancers17040693.
Duangkaew C, Somwangprasert A, Watcharachan K, Wongmaneerung P, Ko-Iam W, Kaweewan I
Cancers (Basel). 2025; 17(4).
PMID: 40002186
PMC: 11852543.
DOI: 10.3390/cancers17040591.
Zeng H, Lv H, Zhang M, Niu L, Wang J, Sun H
J Cancer Res Clin Oncol. 2025; 151(2):89.
PMID: 39979499
PMC: 11842397.
DOI: 10.1007/s00432-025-06133-w.
Plant-derived extracellular vesicles as nanocarriers for combination therapy enhancing paclitaxel-based regimens in breast cancer.
Song Y, Kong H, Oh S, Kim S
BMB Rep. 2025; 58(2):53-63.
PMID: 39978779
PMC: 11875746.
Trends and Disparities in the Use of Immunotherapy for Triple-Negative Breast Cancer in the US.
Freeman J, Huo D, Shubeck S, Chen N, Yarlagadda S, Nanda R
JAMA Netw Open. 2025; 8(2):e2460243.
PMID: 39960669
PMC: 11833518.
DOI: 10.1001/jamanetworkopen.2024.60243.
ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Hu X, Zhang Q, Wang L, Zhang J, Ouyang Q, Wang X
Signal Transduct Target Ther. 2025; 10(1):56.
PMID: 39956849
PMC: 11830773.
DOI: 10.1038/s41392-025-02149-3.
Anticancer-Drug-Related Cardiotoxicity from Adjuvant Goserelin and Tamoxifen Therapy.
Manfrini O, Cenko E, Bergami M, Yoon J, Kostadinovic J, Zdravkovic D
J Clin Med. 2025; 14(2).
PMID: 39860490
PMC: 11766263.
DOI: 10.3390/jcm14020484.
Role of Absorbable Polysaccharide Hemostatic Powder in the Prevention of Complications After Axillary Lymph Node Dissection in Breast Cancer Patients: A Multicenter Retrospective Analysis.
Parisi S, Lucido F, Fisone F, Ruggiero R, Tolone S, Iovino F
Medicina (Kaunas). 2025; 61(1).
PMID: 39859061
PMC: 11766874.
DOI: 10.3390/medicina61010079.
Risk Factors for Treatment Toxicity and High Side Effect Burden Among Breast Cancer Survivors: A Retrospective Chart Review.
Alkhaifi M, Zhang E, Peera M, Jerzak K, Czarnota G, Eisen A
Cancers (Basel). 2025; 17(2).
PMID: 39858109
PMC: 11764302.
DOI: 10.3390/cancers17020328.
Triple-negative breast cancer patients treated with subcutaneous mastectomy with immediate reconstruction: single institution experience.
Bocian A, Macek P, Kedzierawski P
Prz Menopauzalny. 2025; 23(4):192-199.
PMID: 39811390
PMC: 11726194.
DOI: 10.5114/pm.2024.145951.
Retrospective comparative survival analysis of ablation plus systemic therapy versus systemic therapy alone for breast cancer liver metastases, stratified by extrahepatic metastases status.
Zou X, Zou H, Luo X, Chen X, Huang W, Zhang C
Breast. 2025; 79:103876.
PMID: 39808955
PMC: 11782866.
DOI: 10.1016/j.breast.2025.103876.
Hormonal Therapy and Cardiovascular Health: Examining the Risk Among Premenopausal Women Diagnosed With Breast Cancer.
Khosrow-Khavar F, Azoulay L
JACC CardioOncol. 2025; 6(6):919-921.
PMID: 39801651
PMC: 11712015.
DOI: 10.1016/j.jaccao.2024.10.009.
Preoperative comprehensive risk estimation for axillary lymph node metastasis in breast cancer: development and verification of a network-based prediction model.
Sun B, Shao G, Shi M, Sun Z, Wang X, Song Y
Sci Rep. 2025; 15(1):1524.
PMID: 39789023
PMC: 11717927.
DOI: 10.1038/s41598-024-84904-0.
Low-Grade Adenosquamous Carcinoma of the Breast: A Single-Center Retrospective Study and a Systematic Literature Review.
Tamminen A, Bostrom P
Cancers (Basel). 2025; 16(24.
PMID: 39766145
PMC: 11674631.
DOI: 10.3390/cancers16244246.
Predictive markers of rapid disease progression and chemotherapy resistance in triple-negative breast cancer patients following postoperative adjuvant therapy.
Ma T, Hao X, Chen H, Zheng M, Chen X, Cai S
Sci Rep. 2025; 15(1):386.
PMID: 39748017
PMC: 11697311.
DOI: 10.1038/s41598-024-84785-3.
Real world analysis of the efficacy and safety of eribulin compared to utidelone in combination with capecitabine for the treatment of metastatic breast cancer.
Feng M, Bi P, Kang Y, Yang D, Ren S, Lu X
Cancer Cell Int. 2024; 24(1):416.
PMID: 39702163
PMC: 11660865.
DOI: 10.1186/s12935-024-03608-7.
Case report: Prolonged benefit of ESG401, a Trop2 antibody-drug conjugate, in endocrine-refractory hormone receptor-positive, HER-2 negative metastatic breast cancer.
Zhao J, Huang F, Xu X, Zhang Y, Xing X, Huang J
Front Oncol. 2024; 14:1444431.
PMID: 39664178
PMC: 11631905.
DOI: 10.3389/fonc.2024.1444431.
Albumin-To-Alkaline Phosphatase Ratio as a New Early Predictive Marker of Axillary Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Pilot Study.
Schmidt R, Harder Y, Rossi L, Canino P, Schiaffino S, Calcinotto A
Medicina (Kaunas). 2024; 60(11).
PMID: 39596952
PMC: 11596826.
DOI: 10.3390/medicina60111767.
